Qiagen NV (QGEN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $10.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Qiagen NV (QGEN) P/E Ratio & Valuation History
Qiagen NV (QGEN) trades at 20.5x trailing earnings and 4.9x sales. Its P/E of 20.5x is above its 5-year median of 18.5x. Its forward P/E is 15.5x. The median P/E across 10 similar companies is 33.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 32.3% higher over the next year. Its free cash flow yield is 4.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 20.5x |
| Forward P/E | 15.5x |
| Price to sales | 4.9x |
| Price to book | 3.0x |
| EV/EBITDA | 15.9x |
| Price to FCF | 23.9x |
| EV/FCF | 25.8x |
| PEG | 1.3 |
| FCF yield | 4.2% |
Historical Medians
Against its 10-year medians, its P/E is 4.6% above 19.6x, its P/S is 5.8% below 5.2x and its P/B is in line.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 20.5x | 18.5x | 19.6x |
| P/S | 4.9x | 4.9x | 5.2x |
| P/B | 3.0x | 2.8x | 3.0x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 18.2x in 2025 to 23.0x in 2018. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $44.97 | 18.2x | 4.6x | 2.5x |
| 2024 | $44.53 | 18.9x | 5.0x | 2.7x |
| 2023 | $43.43 | 18.9x | 4.9x | 2.6x |
| 2022 | $49.87 | 18.9x | 5.3x | 3.2x |
| 2021 | $55.58 | 18.7x | 5.7x | 4.2x |
| 2020 | $52.85 | 22.0x | 6.6x | 4.4x |
| 2019 | $33.80 | 21.0x | 5.1x | 3.1x |
| 2018 | $34.45 | 23.0x | 5.4x | 3.0x |
| 2017 | $30.93 | 22.3x | 5.1x | 2.8x |
| 2016 | $28.02 | 21.9x | 5.0x | 2.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About QGEN
What is QGEN's forward P/E ratio?
Qiagen NV has a forward P/E ratio of 15.5x.
Is QGEN stock overvalued?
GNG's valuation label for QGEN is Fairly valued. Its P/E of 20.5x compares with a median of 33.8x across 10 similar companies.
What is QGEN's price to sales ratio?
Qiagen NV has a price to sales ratio of 4.9x.
What is Qiagen NV's average P/E ratio over 5 years?
Qiagen NV's median P/E over the last 5 years is 18.5x, from 60 month-end values through Oct 2026.
What is QGEN's PEG ratio?
Qiagen NV has a PEG ratio of 1.3.
QGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts